Home The Word Brain	My Amedeo FAQ Privacy About
	As of October 2023, Amedeo had 12,263 active subscribers

Hepatitis

Free Subscription Articles published in Clin Infect Dis Retrieve available abstracts of 88 articles: HTML format

Single Articles

November 2023
1. VINIKOOR MJ, Hamusonde K, Muula G, Asombang M, et al
   Long-term hepatitis B and liver outcomes among adults taking tenofovir-containing antiretroviral therapy for HBV/HIV coinfection in Zambia.
   Clin Infect Dis. 2023 Nov 24:ciad654. doi: 10.1093.
   PubMed     Abstract available
   
   
   
2. MIDGARD H, Malme KB, Pihl CM, Berg-Pedersen RM, et al
   Opportunistic treatment of hepatitis C infection among hospitalized people who inject drugs (OPPORTUNI-C): A stepped wedge cluster randomized trial.
   Clin Infect Dis. 2023 Nov 22:ciad711. doi: 10.1093.
   PubMed     Abstract available
   
   
   
3. ROWAN SE, Wyles DL
   Don't put off until tomorrow what you can do today: Hospital admissions as an opportunity to treat hepatitis C.
   Clin Infect Dis. 2023 Nov 22:ciad712. doi: 10.1093.
   PubMed    
   
   
   October 2023
4. WONG RJ, Yang Z, Cheung R
   Disparities in Antiviral Treatment among Adults with Hepatitis B Cirrhosis: An Analysis of the National Veterans Affairs Cohort.
   Clin Infect Dis. 2023 Oct 9:ciad617. doi: 10.1093.
   PubMed     Abstract available
   
   
   September 2023
5. YANG J, Lo NC, Dankwa EA, Donnelly CA, et al
   Determining herd immunity thresholds for hepatitis A virus transmission to inform vaccination strategies among people who inject drugs in 16 U.S. States.
   Clin Infect Dis. 2023 Sep 21:ciad552. doi: 10.1093.
   PubMed     Abstract available
   
   
   August 2023
6. TAO Y, Tang W, Fajardo E, Cheng M, et al
   Reflex Hepatitis C Virus Viral Load Testing Following an Initial Positive Hepatitis C Virus Antibody Test: A Global Systematic Review and Meta-analysis.
   Clin Infect Dis. 2023 Aug 31:ciad126. doi: 10.1093.
   PubMed     Abstract available
   
   
   
7. KAPADIA SN, Jordan AE, Eckhardt BJ, Perlman DC, et al
   The urgent need to implement point-of-care RNA testing for hepatitis C virus to support elimination.
   Clin Infect Dis. 2023 Aug 27:ciad503. doi: 10.1093.
   PubMed     Abstract available
   
   
   
8. PETERS MG, Yuen MF, Terrault N, Fry J, et al
   Chronic Hepatitis B Finite Treatment: similar and different concerns with new drug classes.
   Clin Infect Dis. 2023 Aug 26:ciad506. doi: 10.1093.
   PubMed     Abstract available
   
   
   
9. HSU CC, Gopalakrishna H, Mironova M, Lee MH, et al
   Risk of Hepatocellular Carcinoma After Spontaneous Clearance of Hepatitis C Virus and in Noncirrhosis Chronic Hepatitis C Patients With Sustained Virological Response: A Systematic Review.
   Clin Infect Dis. 2023;77.
   PubMed     Abstract available
   
   
   
10. FELD JJ, Bruneau J, Dore GJ, Ghany MG, et al
    Controlled Human Infection Model for Hepatitis C Virus Vaccine Development: Trial Design Considerations.
    Clin Infect Dis. 2023;77.
    PubMed     Abstract available
    
    
    
11. LIANG TJ, Law JLM, Pietschmann T, Ray SC, et al
    Challenge Inoculum for Hepatitis C Virus Controlled Human Infection Model.
    Clin Infect Dis. 2023;77.
    PubMed     Abstract available
    
    
    
12. BILINSKI A, Slimovitch R, Mendlowitz A, Feld JJ, et al
    First Do No Harm? Modeling Risks and Benefits of Challenge Trials for Hepatitis C Vaccine Development.
    Clin Infect Dis. 2023;77.
    PubMed     Abstract available
    
    
    
13. SHOUKRY NH, Cox AL, Walker CM
    Immunological Monitoring in Hepatitis C Virus Controlled Human Infection Model.
    Clin Infect Dis. 2023;77.
    PubMed     Abstract available
    
    
    
14. LIANG TJ, Feld JJ, Shoukry NH, Thomas DL, et al
    Controlled Human Infection Model for Hepatitis C Virus Vaccine Development: Is It Time to Be Real?
    Clin Infect Dis. 2023;77.
    PubMed    
    
    
    
15. EBERTS JD, Zimmer-Harwood P, Elsey JWB, Fraser-Urquhart A, et al
    Volunteering for Infection: Participant Perspectives on a Hepatitis C Virus Controlled Human Infection Model.
    Clin Infect Dis. 2023;77.
    PubMed     Abstract available
    
    
    
16. MARTINELLO M, Naggie S, Rockstroh JK, Matthews GV, et al
    Direct-Acting Antiviral Therapy for Treatment of Acute and Recent Hepatitis C Virus Infection: A Narrative Review.
    Clin Infect Dis. 2023;77.
    PubMed     Abstract available
    
    
    
17. RID A, Feld JJ, Liang TJ, Weijer C, et al
    Ethics of Controlled Human Infection Studies With Hepatitis C Virus.
    Clin Infect Dis. 2023;77.
    PubMed     Abstract available
    
    
    July 2023
18. HOFMEISTER MG, Zhong Y, Moorman AC, Samuel CR, et al
    Temporal trends in hepatitis C-related hospitalizations, United States, 2000-2019.
    Clin Infect Dis. 2023 Jul 18:ciad425. doi: 10.1093.
    PubMed     Abstract available
    
    
    
19. LEWIS KC, Barker LK, Jiles R, Gupta N, et al
    Estimated prevalence and awareness of hepatitis C virus infection among U.S. adults- National Health and Nutrition Examination Survey, January 2017-March 2020.
    Clin Infect Dis. 2023 Jul 7:ciad411. doi: 10.1093.
    PubMed     Abstract available
    
    
    May 2023
20. BHATTACHARYA D, Aronsohn A, Price J, Lo Re V, et al
    Hepatitis C Guidance 2023 Update: AASLD-IDSA Recommendations for Testing, Managing, and Treating Hepatitis C Virus Infection.
    Clin Infect Dis. 2023 May 25:ciad319. doi: 10.1093.
    PubMed     Abstract available
    
    
    April 2023
21. DE REZENDE IM, McClure MA, Pereira LS, Fradico JRB, et al
    Characterization and investigation of risk factors for Late-relapsing hepatitis after yellow fever.
    Clin Infect Dis. 2023 Apr 26:ciad249. doi: 10.1093.
    PubMed     Abstract available
    
    
    
22. GVINJILIA L, Baliashvili D, Shadaker S, Averhoff F, et al
    Impact of HCV infection and treatment on mortality in the country of Georgia, 2015-2020.
    Clin Infect Dis. 2023 Apr 26:ciad182. doi: 10.1093.
    PubMed     Abstract available
    
    
    
23. LAUTREDOU CC, Dao B, Gounder P
    Epidemiology of Suspected and Confirmed Acute Hepatitis E Cases Reported among Los Angeles County Residents, 2017-2019.
    Clin Infect Dis. 2023 Apr 24:ciad242. doi: 10.1093.
    PubMed     Abstract available
    
    
    
24. CHEN GJ, Sun HY, Lin KY, Hsieh SM, et al
    A randomized clinical trial of one-dose versus accelerated two-dose schedule for hepatitis A virus revaccination among people with HIV who were non-responders or had seroreversion after primary HAV vaccination.
    Clin Infect Dis. 2023 Apr 10:ciad206. doi: 10.1093.
    PubMed     Abstract available
    
    
    
25. EDMONDS A, Haley DF, Edwards JK, Ramirez C, et al
    Health Insurance and Initiation of Direct-Acting Antivirals for Hepatitis C in US Women with HIV.
    Clin Infect Dis. 2023 Apr 6:ciad204. doi: 10.1093.
    PubMed     Abstract available
    
    
    
26. MARKS KM, Kang M, Umbleja T, Avihingsanon A, et al
    Immunogenicity and Safety of Hepatitis B vaccine with a Toll-like Receptor 9 Agonist Adjuvant (HEPLISAV-B) in HBV Vaccine-naive People with HIV.
    Clin Infect Dis. 2023 Apr 5:ciad201. doi: 10.1093.
    PubMed     Abstract available
    
    
    March 2023
27. BEISER ME, Shaw LC, Shores SK, Carson JM, et al
    Hepatitis C virus reinfection in a real-world cohort of homeless-experienced individuals in Boston.
    Clin Infect Dis. 2023 Mar 4:ciad127. doi: 10.1093.
    PubMed     Abstract available
    
    
    February 2023
28. GONSALVES GS, Paltiel AD, Thornhill T, DeMaria A, et al
    Patterns of Infectious Disease Associated with Injection Drug Use in Massachusetts.
    Clin Infect Dis. 2023 Feb 9:ciad073. doi: 10.1093.
    PubMed     Abstract available
    
    
    January 2023
29. HERNANDEZ-TAMAYO C, Qato DM, Jewell MP, Gounder P, et al
    COVID-19 Pandemic Associated Declines and Subsequent Increases in Hepatitis C Virus Treatment Prescriptions in Los Angeles County.
    Clin Infect Dis. 2023 Jan 31:ciad050. doi: 10.1093.
    PubMed    
    
    
    
30. SOWAH LA, Smeaton L, Brates I, Bhattacharya D, et al
    Perspectives on Adherence from the ACTG 5360 MINMON Trial: A Minimum Monitoring Approach with 12 Weeks of Sofosbuvir/Velpatasvir in Chronic Hepatitis C Treatment.
    Clin Infect Dis. 2023 Jan 24:ciad034. doi: 10.1093.
    PubMed     Abstract available
    
    
    
31. AHRENS K, Sharbaugh M, Jarlenski MP, Tang L, et al
    Prevalence of testing for HIV, HBV, and HCV among Medicaid enrollees treated with medications for opioid use disorder in 11 states, 2016-2019.
    Clin Infect Dis. 2023 Jan 3:ciac981. doi: 10.1093.
    PubMed     Abstract available
    
    
    December 2022
32. POLITI J, Regidor E, Donat M, Pulido J, et al
    Free access to direct-acting antivirals in Spain: more favorable impact on hepatitis C mortality among highly educated people.
    Clin Infect Dis. 2022 Dec 6:ciac928. doi: 10.1093.
    PubMed     Abstract available
    
    
    November 2022
33. THOMAS DL, Kiser JJ, Baum MM
    Long-Acting Treatments for Hepatitis B.
    Clin Infect Dis. 2022;75.
    PubMed     Abstract available
    
    
    
34. OLAGUNJU A, Mathad J, Eke A, Delaney-Moretlwe S, et al
    Considerations for the Use of Long-Acting and Extended-Release Agents During Pregnancy and Lactation.
    Clin Infect Dis. 2022;75.
    PubMed     Abstract available
    
    
    
35. THOMAS DL, Owen A, Kiser JJ
    Prospects for Long-Acting Treatments for Hepatitis C.
    Clin Infect Dis. 2022;75.
    PubMed     Abstract available
    
    
    October 2022
36. HOFMANN E, Surial B, Boillat-Blanco N, Gunthard HF, et al
    HBV REPLICATION DURING TENOFOVIR THERAPY IS FREQUENT IN HIV/HBV-COINFECTION.
    Clin Infect Dis. 2022 Oct 15. pii: 6761485. doi: 10.1093.
    PubMed     Abstract available
    
    
    
37. JACOB JS, Shaikh A, Goli K, Rich NE, et al
    Improved Survival after Liver Transplantation for Patients with HIV and HIV/HCV Coinfection in the INSTI and DAA eras.
    Clin Infect Dis. 2022 Oct 12. pii: 6758523. doi: 10.1093.
    PubMed     Abstract available
    
    
    September 2022
38. BALIASHVILI D, Blumberg HM, Benkeser D, Kempker RR, et al
    Association of treated and untreated chronic hepatitis C with the incidence of active tuberculosis disease: a population-based cohort study.
    Clin Infect Dis. 2022 Sep 22. pii: 6711147. doi: 10.1093.
    PubMed     Abstract available
    
    
    
39. CHEW KW, Wu K, Tassiopoulos K, Palella FJ, et al
    Liver inflammation is common and linked to metabolic derangements in persons with treated HIV.
    Clin Infect Dis. 2022 Sep 1. pii: 6682837. doi: 10.1093.
    PubMed     Abstract available
    
    
    August 2022
40. MONIN MB, Ingiliz P, Lutz T, Scholten S, et al
    Low spontaneous clearance rates of recently acquired hepatitis C virus in HIV-positive MSM (The PROBE-C Study).
    Clin Infect Dis. 2022 Aug 25. pii: 6675078. doi: 10.1093.
    PubMed     Abstract available
    
    
    July 2022
41. HUDSON AG, Bonacci RA, Moorman AC, Penley M, et al
    Hepatitis C virus infection preceding an outbreak of HIV among persons who inject drugs- Kanawha County, West Virginia, 2019-2021.
    Clin Infect Dis. 2022 Jul 29. pii: 6651445. doi: 10.1093.
    PubMed     Abstract available
    
    
    
42. HSU HY, Chen HL, Chiang CL, Lai MW, et al
    Characterization of Hepatitis B Virus in Tenofovir-Treated and Untreated Chronically Infected Mothers and Their Immunoprophylaxis Failure Infants.
    Clin Infect Dis. 2022 Jul 5. pii: 6629403. doi: 10.1093.
    PubMed     Abstract available
    
    
    
43. MARATHE G, Moodie EE, Brouillette MJ, Delaunay CL, et al
    Impact of HCV cure on depressive symptoms in the HIV-HCV co-infected population in Canada.
    Clin Infect Dis. 2022 Jul 5. pii: 6629407. doi: 10.1093.
    PubMed     Abstract available
    
    
    May 2022
44. MAK LY, Cheung KS, Hui RW, Wong DK, et al
    Enhanced liver fibrosis score stratifies hepatocellular carcinoma risk in patients with hepatitis B surface antigen seroclearance.
    Clin Infect Dis. 2022 May 20. pii: 6589789. doi: 10.1093.
    PubMed     Abstract available
    
    
    
45. CHOW N, Wong D, Lai CL, Mak LY, et al
    Effect of antiviral treatment on hepatitis B virus integration and hepatocyte clonal expansion.
    Clin Infect Dis. 2022 May 20. pii: 6589784. doi: 10.1093.
    PubMed     Abstract available
    
    
    
46. WONG RJ, Kaufman HW, Niles JK, Kapoor H, et al
    Simplifying Treatment Criteria in Chronic Hepatitis B: Reducing Barriers to Elimination.
    Clin Infect Dis. 2022 May 20. pii: 6589786. doi: 10.1093.
    PubMed     Abstract available
    
    
    April 2022
47. JHAVERI R
    Elimination Means Everyone: Targeting Hepatitis C in Infants and Pregnant Patients.
    Clin Infect Dis. 2022 Apr 27. pii: 6574818. doi: 10.1093.
    PubMed    
    
    
    
48. JOHANNESSON JM, Fridriksdottir RH, Love TJ, Runarsdottir V, et al
    HIGH RATE OF HCV REINFECTION AMONG RECENTLY INJECTING DRUG USERS: RESULTS FROM THE TRAP HEP C PROGRAM - A PROSPECTIVE NATIONWIDE, POPULATION-BASED STUDY.
    Clin Infect Dis. 2022 Apr 19. pii: 6570478. doi: 10.1093.
    PubMed     Abstract available
    
    
    
49. GROVES J, Dodd RY, Foster GA, Stramer SL, et al
    Genotype Distribution and Demographic Characteristics of Hepatitis C Virus NAT Yield Cases among US Blood Donors.
    Clin Infect Dis. 2022 Apr 11. pii: 6566326. doi: 10.1093.
    PubMed     Abstract available
    
    
    
50. KUSEJKO K, Salazar-Vizcaya L, Shah C, Stockle M, et al
    Sustained effect on hepatitis C elimination among men who have sex with men in the Swiss HIV Cohort Study: A systematic re-screening for hepatitis C RNA two years following a nation-wide elimination program.
    Clin Infect Dis. 2022 Apr 11. pii: 6566325. doi: 10.1093.
    PubMed     Abstract available
    
    
    
51. ADES AE, Gordon F, Scott K, Collins IJ, et al
    Overall vertical transmission of HCV, transmission net of clearance, and timing of transmission.
    Clin Infect Dis. 2022 Apr 11. pii: 6566315. doi: 10.1093.
    PubMed     Abstract available
    
    
    
52. ADES AE, Gordon F, Scott K, Collins IJ, et al
    Spontaneous Clearance Of Vertically Acquired Hepatitis C Infection: Implications For Testing And Treatment.
    Clin Infect Dis. 2022 Apr 9. pii: 6565752. doi: 10.1093.
    PubMed     Abstract available
    
    
    
53. CARSON JM, Dore GJ, Lloyd AR, Grebely J, et al
    Hepatitis C virus reinfection following direct acting antiviral treatment in the prison setting: the SToP-C study.
    Clin Infect Dis. 2022 Apr 1. pii: 6562011. doi: 10.1093.
    PubMed     Abstract available
    
    
    March 2022
54. AMIN J, Vaccher S, Templeton DJ, Bavinton B B, et al
    Low prior exposure and incidence of hepatitis C in HIV negative gay and bisexual men taking PrEP: findings from the EPIC-NSW prospective implementation study.
    Clin Infect Dis. 2022 Mar 30. pii: 6555792. doi: 10.1093.
    PubMed     Abstract available
    
    
    
55. LEE TH, Hunt CM, Maier MM, Lowy E, et al
    Hepatitis B Virus-Related Care Quality In Patients With Hepatitis B/Hiv Coinfection Versus Hepatitis B Monoinfection: A National Cohort Study.
    Clin Infect Dis. 2022 Mar 29. pii: 6555659. doi: 10.1093.
    PubMed     Abstract available
    
    
    
56. MOUTCHIA J, Njouom R, Rumpler E, Besombes C, et al
    Maternal Age at First Childbirth and Geographical Variation in Hepatitis B Virus Prevalence in Cameroon: Important Role of Mother-to-Child Transmission.
    Clin Infect Dis. 2022;74:836-845.
    PubMed     Abstract available
    
    
    
57. HOENIGL M, Abramovitz D, Flores Ortega RE, Martin NK, et al
    Sustained impact of the COVID-2019 pandemic on HCV treatment initiations in the United States.
    Clin Infect Dis. 2022 Mar 2. pii: 6540915. doi: 10.1093.
    PubMed     Abstract available
    
    
    February 2022
58. TRICKEY A, Croxford S, Emanuel E, Ijaz S, et al
    The effectiveness of low dead space syringes for reducing the risk of hepatitis C virus acquisition among people who inject drugs - findings from a national survey in England, Wales, and Northern Ireland.
    Clin Infect Dis. 2022 Feb 20. pii: 6532589. doi: 10.1093.
    PubMed     Abstract available
    
    
    
59. TESHALE EH, Roberts H, Gupta N, Jiles R, et al
    Characteristics of persons treated for hepatitis C using national pharmacy claims data, United States, 2014-2020.
    Clin Infect Dis. 2022 Feb 16. pii: 6529537. doi: 10.1093.
    PubMed     Abstract available
    
    
    
60. GORDON SC, Teshale EH, Spradling PR, Moorman AC, et al
    Lower rates of emergency visits and hospitalizations among chronic hepatitis C patients with sustained virological response to interferon-free direct-acting antiviral therapy (2014-2018).
    Clin Infect Dis. 2022 Feb 11. pii: 6526938. doi: 10.1093.
    PubMed     Abstract available
    
    
    December 2021
61. HUANG YC, Sun HY, Sheng WH, Hsieh SM, et al
    Evolution of hepatitis B virus (HBV) serologic markers among antiretroviral-naive, young people living with HIV who had undergone neonatal HBV vaccination and initiated antiretroviral therapy.
    Clin Infect Dis. 2021 Dec 10. pii: 6459150. doi: 10.1093/cid/ciab1020.
    PubMed     Abstract available
    
    
    
62. LIU CJ, Sheen IS, Chen CY, Chuang WL, et al
    Ledipasvir/Sofosbuvir for Patients Coinfected With Chronic Hepatitis C and Hepatitis B in Taiwan: Follow-up 108 Weeks Posttreatment.
    Clin Infect Dis. 2021 Dec 2. pii: 6448442. doi: 10.1093.
    PubMed     Abstract available
    
    
    November 2021
63. LIU S, Deng R, Zhou B, Sun J, et al
    Is the World Health Organization Hepatitis B Virus (HBV) DNA Standard Appropriate for Standardizing Serum HBV RNA Assays?
    Clin Infect Dis. 2021;73:e2821-e2823.
    PubMed    
    
    
    
64. WORETA TA, Chalasani N
    Fatty Liver Disease in Human Immunodeficiency Virus-Hepatitis B Virus Coinfection: A Cause for Concern.
    Clin Infect Dis. 2021;73:e3286-e3287.
    PubMed    
    
    
    
65. LEE JH, Lee YB, Cho EJ, Yu SJ, et al
    Entecavir Plus Pegylated Interferon and Sequential Hepatitis B Virus Vaccination Increases Hepatitis B Surface Antigen Seroclearance: A Randomized Controlled Proof-of-Concept Study.
    Clin Infect Dis. 2021;73:e3308-e3316.
    PubMed     Abstract available
    
    
    October 2021
66. SRIDHAR S, Yip CC, Lo KH, Wu S, et al
    Hepatitis E virus species C infection in humans, Hong Kong.
    Clin Infect Dis. 2021 Oct 27. pii: 6412704. doi: 10.1093.
    PubMed     Abstract available
    
    
    
67. WELD ED, Astemborski J, Kirk GD, Sulkowski MS, et al
    Preferences of Persons with or at Risk for Hepatitis C for Long-Acting Treatments.
    Clin Infect Dis. 2021 Oct 26. pii: 6410743. doi: 10.1093.
    PubMed     Abstract available
    
    
    
68. KHALILI M, King WC, Kleiner DE, Chung RT, et al
    Evolution of Fatty Liver Disease and Relationship With Lipoproteins and Clinical Outcomes in Hepatitis B/Human Immunodeficiency Virus Coinfection.
    Clin Infect Dis. 2021 Oct 25. pii: 6410628. doi: 10.1093.
    PubMed     Abstract available
    
    
    
69. HARNEY BL, Sacks-Davis R, van Santen DK, Traeger M, et al
    The Incidence of Hepatitis C Among Gay, Bisexual, and Other Men Who Have Sex With Men in Australia, 2009-2019.
    Clin Infect Dis. 2021 Oct 25. pii: 6410633. doi: 10.1093.
    PubMed     Abstract available
    
    
    September 2021
70. BAROCAS JA, Savinkina A, Lodi S, Epstein RL, et al
    Projected long-term impact of the COVID-19 pandemic on hepatitis C outcomes in the United States: a modelling study.
    Clin Infect Dis. 2021 Sep 9. pii: 6367757. doi: 10.1093.
    PubMed     Abstract available
    
    
    
71. GAO Y, Kong F, Song X, Shang J, et al
    Pradefovir Treatment in Patients with Chronic Hepatitis B: Week 24 Results from a Multicenter, Double-blind, Randomized, Noninferiority, Phase 2 Trial.
    Clin Infect Dis. 2021 Sep 6. pii: 6364928. doi: 10.1093.
    PubMed     Abstract available
    
    
    August 2021
72. TULLY DC, Hahn JA, Bean DJ, Evans JL, et al
    Identification of Genetically Related HCV Infections Among Self-Described Injecting Partnerships.
    Clin Infect Dis. 2021 Aug 27. pii: 6358610. doi: 10.1093.
    PubMed     Abstract available
    
    
    
73. LIU L, Wang L, Zhang H, Ou W, et al
    Changing Epidemiology of Hepatitis B Virus and Hepatitis C Virus Coinfection in a Human Immunodeficiency Virus-Positive Population in China: Results From the Third and Fourth Nationwide Molecular Epidemiologic Surveys.
    Clin Infect Dis. 2021;73:642-649.
    PubMed     Abstract available
    
    
    July 2021
74. GORMLEY MA, Akiyama MJ, Rennert L, Howard KA, et al
    Changes in health-related quality of life for HCV-infected people who inject drugs on opioid agonist treatment following sustained virologic response.
    Clin Infect Dis. 2021 Jul 31. pii: 6332893. doi: 10.1093.
    PubMed     Abstract available
    
    
    
75. IJAZ S, Derrick J, Shute J, Ireland G, et al
    Mother To Infant Transmission Of Hepatitis B Virus In The Face Of Neonatal Immunisation Is Not Necessarily Primary Vaccine Failure.
    Clin Infect Dis. 2021 Jul 12. pii: 6319332. doi: 10.1093.
    PubMed     Abstract available
    
    
    
76. DEZANET LNC, Kassime R, Miailhes P, Lascoux-Combe C, et al
    Effect of viral replication and liver fibrosis on all-cause mortality in HIV/HBV coinfected individuals: a retrospective analysis of a 15-year longitudinal cohort.
    Clin Infect Dis. 2021 Jul 1. pii: 6312684. doi: 10.1093.
    PubMed     Abstract available
    
    
    June 2021
77. BARTLETT SR, Wong S, Yu A, Pearce M, et al
    The impact of current opioid agonist therapy on hepatitis C virus treatment initiation among people who use drugs from in the DAA era: A population-based study.
    Clin Infect Dis. 2021 Jun 14. pii: 6298569. doi: 10.1093.
    PubMed     Abstract available
    
    
    
78. VALERIO H, Alavi M, Law M, McManus H, et al
    Opportunities to enhance linkage to hepatitis C care among hospitalised people with recent drug dependence in New South Wales, Australia: A population-based linkage study.
    Clin Infect Dis. 2021 Jun 9. pii: 6295650. doi: 10.1093.
    PubMed     Abstract available
    
    
    
79. ONOFRIO FQ, Cooper C, Borgia SM, Vachon ML, et al
    Salvage Therapy with Sofosbuvir/Velpatasvir/Voxilaprevir in DAA-experienced Patients: Results from a Prospective Canadian Registry.
    Clin Infect Dis. 2021;72:e799-e805.
    PubMed     Abstract available
    
    
    May 2021
80. BOEKE CE, Hiebert L, Waked I, Tsertsvadze T, et al
    Retreatment of Chronic Hepatitis C Infection: Real-World Regimens and Outcomes from National Treatment Programs in Three Low- and Middle-Income Countries.
    Clin Infect Dis. 2021 May 20. pii: 6279051. doi: 10.1093.
    PubMed     Abstract available
    
    
    
81. TOY M, Hutton D, Harris AM, Nelson N, et al
    Cost-Effectiveness of One-Time Universal Screening for Chronic Hepatitis B Infection in Adults in the United States.
    Clin Infect Dis. 2021 May 6. pii: 6270943. doi: 10.1093.
    PubMed     Abstract available
    
    
    April 2021
82. HEO M, Pericot-Valverde I, Rennert L, Akiyama MJ, et al
    Hepatitis C virus DAA treatment adherence patterns and SVR among people who inject drugs treated in opioid agonist therapy programs.
    Clin Infect Dis. 2021 Apr 20. pii: 6238636. doi: 10.1093.
    PubMed     Abstract available
    
    
    
83. MERAT S, Sharifi AH, Poustchi H, Hajiani E, et al
    Erratum to: SD1000: High Sustained Viral Response Rate in 1361 Patients With Hepatitis C Genotypes 1, 2, 3, and 4 Using a Low-cost Fixed-dose Combination Tablet of Generic Sofosbuvir and Daclatasvir: A Multicenter Phase III Clinical Trial.
    Clin Infect Dis. 2021 Apr 15. pii: 6226813. doi: 10.1093/cid/ciaa1768.
    PubMed    
    
    
    
84. LEE SK, Sung PS, Park SS, Min CK, et al
    Reactivation of resolved hepatitis B after daratumumab for multiple myeloma.
    Clin Infect Dis. 2021 Apr 13. pii: 6224403. doi: 10.1093.
    PubMed     Abstract available
    
    
    July 2020
85. ZHANG H, Wang F, Zhu X, Chen Y, et al
    Antiviral Activity and Pharmacokinetics of the HBV Capsid Assembly Modulator GLS4 in Patients with Chronic HBV Infection.
    Clin Infect Dis. 2020 Jul 10. pii: 5869864. doi: 10.1093.
    PubMed     Abstract available
    
    
    June 2020
86. CHANCHAROENTHANA W, Leelahavanichkul A
    Kidney Transplantation from HBsAg+ Living Donors to HBsAg- Recipients: Benefits and Risks.
    Clin Infect Dis. 2020 Jun 3. pii: 5850914. doi: 10.1093.
    PubMed    
    
    
    February 2020
87. WANG XD, Liu JP, Song TR, Huang ZL, et al
    Kidney Transplantation from HBsAg+ Living Donors to HBsAg- Recipients: Clinical Outcomes at a High-volume Center in China.
    Clin Infect Dis. 2020 Feb 26. pii: 5758069. doi: 10.1093.
    PubMed     Abstract available
    
    
    December 2019
88. BOGLIONE L, Lipani F, Lucchini AM, Salvador E, et al
    Antiviral therapy in patients with HBV treated for tuberculosis: a forgotten issue.
    Clin Infect Dis. 2019 Dec 17. pii: 5679635. doi: 10.1093/cid/ciz1199.
    PubMed    
    
    

Thank you for your interest in scientific medicine.

AMEDEO Hepatitis is free of charge.